GLMD vs. TRIB, ATHA, BGXX, BCDA, EQ, SNSE, LPTX, BTAI, XFOR, and PHXM
Should you be buying Galmed Pharmaceuticals stock or one of its competitors? The main competitors of Galmed Pharmaceuticals include Trinity Biotech (TRIB), Athira Pharma (ATHA), Bright Green (BGXX), BioCardia (BCDA), Equillium (EQ), Sensei Biotherapeutics (SNSE), Leap Therapeutics (LPTX), BioXcel Therapeutics (BTAI), X4 Pharmaceuticals (XFOR), and PHAXIAM Therapeutics (PHXM). These companies are all part of the "pharmaceutical products" industry.
Galmed Pharmaceuticals vs. Its Competitors
Trinity Biotech (NASDAQ:TRIB) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.
Galmed Pharmaceuticals has a net margin of 0.00% compared to Trinity Biotech's net margin of -51.64%. Trinity Biotech's return on equity of 0.00% beat Galmed Pharmaceuticals' return on equity.
In the previous week, Trinity Biotech had 1 more articles in the media than Galmed Pharmaceuticals. MarketBeat recorded 1 mentions for Trinity Biotech and 0 mentions for Galmed Pharmaceuticals. Trinity Biotech's average media sentiment score of 0.00 equaled Galmed Pharmaceuticals'average media sentiment score.
Galmed Pharmaceuticals has lower revenue, but higher earnings than Trinity Biotech. Trinity Biotech is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
79.0% of Trinity Biotech shares are owned by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are owned by institutional investors. 8.2% of Trinity Biotech shares are owned by insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Trinity Biotech has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500. Comparatively, Galmed Pharmaceuticals has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500.
Summary
Trinity Biotech beats Galmed Pharmaceuticals on 7 of the 12 factors compared between the two stocks.
Get Galmed Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Galmed Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:GLMD) was last updated on 7/8/2025 by MarketBeat.com Staff
